In recent analyst calls, the rckt stock forecast was upgraded to “Overweight” based on risk-adjusted returns. High beta combined with modest debt levels makes the stock appealing as a speculative growth holding. Livshits reduced the probability of success from 70% to 40%, given CBER leadership’s focus on benefit/risk, pending more details regarding agency feedback and next steps. $RCKT insiders have traded $RCKT stock on the open market 20 times in the past 6 months. Of those trades, 2 have been purchases and 18 have been sales. The rckt stock forecast reflects renewed investor confidence as biotech indexes outperform broader markets. With a current market cap increase of 8% week-over-week, options market pricing implies a high probability for near-term upward breakout beyond $5.